- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06477029
Examination of Transcranial Focused Ultrasound on Brain Activity in Adults
April 24, 2026 updated by: Mary Phillips, MD MD (Cantab)
Modulating Ventral Striatal Activity and Connectivity With Transcranial Focused Ultrasound as a Putative Novel Intervention for Cocaine Use Disorder
The investigators aim to examine the immediate effect of transcranial focused ultrasound (tFUS) on brain activity in healthy adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators will examine ventral striatum (VS) target engagement by tFUS in healthy adults using a reward processing task that reliably activates the VS.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- No present/lifetime history of major depressive disorder (MDD), psychosis, Bipolar Disorder; Hamilton Depression Rating Scale (HDRS)>7; Young Mania Rating Scale (YMRS)>10), borderline personality disorder, and present suicidal ideation
- No family history of MDD, psychosis, Bipolar Disorder, or epilepsy
Exclusion Criteria:
- Present/lifetime history of MDD, psychosis, Bipolar Disorder (HDRS>7; YMRS>10), borderline personality disorder, and present suicidal ideation. Childhood history of, but not present, anxiety disorders and Attention-deficit/hyperactivity disorder (ADHD) will be allowed as these are common disorders in childhood
- Family history of MDD, psychosis, Bipolar Disorder, or epilepsy
- History of head injury, neurological (e.g., epilepsy), pervasive developmental disorder (e.g., autism), systemic medical disease and treatment (medical records, participant report)
- Use of substances with seizure risk (e.g., stimulants) in the past month, as for other non-invasive neuromodulation techniques, assessed as screening and before each tFUS session
- Mini-Mental State Examination (MMSE) score (cognitive state) <24
- Premorbid North American Adult Reading Test (NAART) intelligence quotient (IQ) estimate <85;
- Visual disturbance: <20/40 (Snellen visual acuity)
- Left/mixed handedness (Annett criteria)
- History of alcohol or other substance use disorder (SUD), daily nicotine use, and/or illicit substance use over the last 3 months (SCID-5). Note: lifetime/present cannabis use (<3 times in the past month) at non-SUD levels will be allowed, given its common usage in young adults. Urine tests on scan days will exclude current illicit substance use. Salivary alcohol tests on scan days will exclude intoxicated individuals
- Binge drinking (as defined by National Institute on Alcohol Abuse and Alcoholism (NIAA) criteria: consuming 5 or more drinks (male), or 4 or more drinks (female), in about 2 hours.) in the week before, and/or >3 drinks/day for the 3 days before, and/or alcohol in the last 12 hrs before, any alcohol on tFUS scan day, confirmed at screening and scan days. Alcohol/nicotine/caffeine/cannabis use (below SCID-5 SUD and binge levels) will be allowed
- MRI exclusion criteria: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
- Unable to understand English
- Taking any psychotropic medications in the past 3 months
- Any implanted neural device
- Color blind
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VS tFUS/Sham tFUS
VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
|
tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
Sham tFUS goes through the motions of applying tFUS to the brain.
Participants will know that one session will be a sham, but they will be blinded to which session is the sham
|
|
Experimental: Sham tFUS/VS tFUS
VS tFUS (tFUS applied to the ventral striatum) Sham tFUS (go through the motions of applying tFUS to the VS)
|
tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
Sham tFUS goes through the motions of applying tFUS to the brain.
Participants will know that one session will be a sham, but they will be blinded to which session is the sham
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ventral striatum (VS) activity to prediction error before receiving tFUS to the VS
Time Frame: Two visits over up to 8 weeks
|
Measure of ventral striatum (VS) activity to prediction error before receiving tFUS to the VS
|
Two visits over up to 8 weeks
|
|
Ventral striatum (VS) activity to prediction error after receiving tFUS to the VS
Time Frame: Two visits over up to 8 weeks
|
Measure of ventral striatum (VS) activity to prediction error after receiving tFUS to the VS
|
Two visits over up to 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mary P Phillips, MD MD (Cantab), University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2024
Primary Completion (Actual)
April 13, 2026
Study Completion (Actual)
April 13, 2026
Study Registration Dates
First Submitted
June 20, 2024
First Submitted That Met QC Criteria
June 20, 2024
First Posted (Actual)
June 27, 2024
Study Record Updates
Last Update Posted (Actual)
April 30, 2026
Last Update Submitted That Met QC Criteria
April 24, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY24020142
- UG3DA060431 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data from this study will be available for access by the research community via National Institute of Mental Health Data Archive (NDA).
IPD Sharing Time Frame
After each submission cycle, NDA conducts quality assurance (QA) procedures on submitted data during which access to data and images for research is temporarily suspended, typically a period lasting 4 months prior to sharing.
As required by NDA, studies will also be created that contain the data used for every publication.
Those studies will be shared when the pre-print is available.
NDA studies have digital object identifiers (DOI) to aid findability.
We will include DOI in relevant publications.
NDA will decide how long to preserve the data, but has not deleted any deposited data to date.
IPD Sharing Access Criteria
To request access of the data, researchers will use the standard processes at NDA, and the NDA Data Access Committee will decide which requests to grant.
The standard NDA data access process allows access for one year and is renewable.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impulsive Behavior
-
Martha TillsonNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Michael J. Wesley, PhDRecruitingAlcohol Risk BehaviorsUnited States
-
Sun Yat-sen UniversityNot yet recruitingBehavior, Addictive | College StudentChina
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited Kingdom
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingAddiction | Tobacco-Related CarcinomaUnited States
-
Riphah International UniversityCompletedDrug Use and AddictionPakistan
-
University Hospital, LilleNot yet recruitingPregnant Woman Who Uses TobaccoFrance
-
Centre Hospitalier Charles Perrens, BordeauxRecruitingAddiction | Addictive Behaviors | Addiction DisordersFrance
-
Dow University of Health SciencesCompletedInternet Addiction DisorderPakistan
-
Agnaldo José LopesNot yet recruitingSmoking (Tobacco) AddictionBrazil
Clinical Trials on tFUS
-
Mary Phillips, MD MD (Cantab)WithdrawnImpulsive BehaviorUnited States
-
Medical University of South CarolinaRecruiting
-
Medical University of South CarolinaCompleted
-
University of MinnesotaRecruitingCranial NeurosurgeryUnited States
-
Virginia Polytechnic Institute and State UniversityWithdrawn
-
Medical University of South CarolinaRecruiting
-
Xuanwu Hospital, BeijingNot yet recruiting
-
University of California, Los AngelesRecruitingEssential TremorUnited States
-
University of NottinghamActive, not recruitingStroke | Trauma | Cognition | Agency | Verbal Memory | CCASUnited Kingdom
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Deep Brain Stimulation | Amnestic Mild Cognitive Disorder | Mild Alzheimer's DiseaseUnited States